B3GNT8 (UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8) is a Golgi-localized glycosyltransferase that catalyzes the formation of beta-1,3-N-acetylglucosamine linkages in the biosynthesis of poly-N-acetyllactosamine chains on multiantennary N-glycans 1. The enzyme shows particular activity toward tetraantennary and 2,6 triantennary N-glycan structures, contributing to glycan elongation and complexity. B3GNT8 plays critical roles in maintaining intestinal homeostasis by supporting tight junction integrity, goblet cell mucin secretion, and Paneth cell function through proper glycosylation of lysosomal proteins like LAMP1/2 1. Its deficiency disrupts autophagy-lysosomal processes via the ATG16L1-ATG12-ATG5 pathway and increases susceptibility to colitis 1. Clinically, B3GNT8 expression shows protective associations in several diseases: reduced levels correlate with inflammatory bowel disease progression 1, while higher expression appears protective against aging 2 and atrial fibrillation 3. In cancer contexts, B3GNT8 demonstrates complex roles - it functions as a potential tumor suppressor in pancreatic cancer 4 but shows positive correlations with claudin-3 expression in colorectal cancer through N-glycosylation and receptor tyrosine kinase signaling pathways 5. These findings position B3GNT8 as a therapeutically relevant target across multiple pathological conditions.